Strategic partnerships Biocept collaborates with other biopharma and diagnostics players, evidenced by the Plus Therapeutics collaboration to license CNSide for CNS radiotherapy patients, presenting a clear opportunity to target co-development or licensing deals with oncology and CNS-focused companies.

CNS disease focus The CNSide CSF-based assay targets central nervous system metastases, indicating a strong addressable market among oncologists treating brain and spine metastases, with potential upsell through expanded biomarker panels or longitudinal CSF monitoring services.

Laboratory capabilities Biocept operates a CLIA-certified and CAP-accredited lab, enabling scalable service offerings and reassurance for enterprise clients seeking compliant, high-quality CNS diagnostics support and potential contractual research services.

Clinical utility CNSide provides actionable insights on tumor presence, treatment targets, and response trends in CSF, suggesting opportunities to package integrated diagnostic reports with treatment guidance, supporting payer discussions and value-based pricing.

Financial runway With revenue in the mid-range and funding secured, Biocept has financial breathing room to pursue channel partnerships, expand sales efforts, and pilot new diagnostic panels or collaborations, including government or public health testing programs.